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EXPERIMENTAL STUDIES	
Effects of Flecainide on the Rate Dependence of Atrial Refractoriness,
Atria! Repolarization and Atrioventricular Node Conduction in
Anesthetized Dogs
GILLES O'HARA, MD.' CHRISTINE VILLEMAIRE, MENG,- MARIO TALAJIC, MD,*+
STANLEY NATTEL, MD, FACC*T`+
Montreal. Quebec . Canada
Flecainide is effective against certain supraventricutar arrhyth-
mias (atria) fibrillation and alrioventricular [AV] note reentrant
tachycardia), but its mechanisms of action are unknown. Previous
in vitro work suggests that flerainide attenuates rate-dependent
action potential duration shortening, producing taehycardia-
dependent prolongation of the refractory period . This study was
designed to assess whether similar changes occur in vivo and
whether the effects of flecainide on AV node conduction depend on
heart rate and on direction of propagation (anterograde vs .
retrograde)
.
The effects of flerainide at three clinically relevant concentra-
tions were assessed in open chest, morphine-chloralose-
anesthetized dogs. Flecainide increased atrial refractory period in
a concentration- and rate-related fashion (e.g., dose 3 increased
the atria) effective refractory period by 9 *_ 4% at a cycle length
of 1,000 ms but by 36 t 5% and 55 A 10% at a haste cycle length
of 400 and 300 ms, respectively ; p < 0.001 for each). Flecainide
attenuated the action potential duration accommodation (mea-
sured by monophasic action potentials) to heart rate, causing
tacbyeardia .dependent action potential duration prolongation and
Class IC antiarrhythmic drugs are considered characteristi-
cally to slow conduction without altering refractoriness in
fast channel tissue (1). Basic principles governing the occur-
rence of reentry (2,3) suggest that slowing conduction with-
out altering refractoriness should, if anything. make reentry
more likely . However, recent studies have attested to the
ability of propafenone (4-6) and flecainide (7-14) to termi-
From the *Department of Medicine . Momreai Hear Institute . the FDc-
panment of Medicine . University of Montreal, and the 2Depanmenr of
Pharmacology and Therapeutics . McGill University . Montreal. Quebec
. Can-
ada
. This study was supported by grants from the Medical Research Council
of Canada, Ottawa. Ontario. Canada: the Quebec Heart Foundation, Mo
.-
Foods de Recherche ea Same du Quebec . Moment : RA-3M
Pharmaceuticals, London . Ontario and the Foods de Recherche de I Instimt
de Cardiologie d, Montreal . Montreal. Dr. Nanel is a Nordic-FRSQ Research
Scholar. Moment, and Dr
. Taijic is a Research Scholar of the Canadian
Heart Foundation. Ottawa
. Or
. O'Hara
--,an
FRSQ Research Fellow during
the pedormance .1`06-&
Manuscript received August I'- . 1991
: revised manuscript received No-
vember 4
. 1991, accepted November 15, I99L
Address for reprint :
Stanley Nanel . MD . Moment Heart Institute
. 5010
Relanger Street East. Montreal. Quebec . Caroda. HIT ICS.
D1992 by the American College of Ca1Jiotngy
1335
accounting for most of the rate-dependent atria) effective refrac .
tory period changes
.
Flecainide increased Wenckebach cycle length, but the etmcen-
tralion-response curve was much steeper in the retrograde (slope
41 2 7
mslpmul-literr) than in the anterograde direction 117 !
4 mslpmol .titer- ' ; p < 0.01), indicating more potent effects ore
retrograde conduction . The depressantn action of the drug on the
AV node was also rate dependent, with an effect on the AH
interval at a basic cycle length of 400 res that averaged 1 .0, 1 .5
and 2 times that at a basic cycle length of 1,000 ms for dates I
to
< 0
.051, 2 (p < 0 .01) and 3 it, < 0 .001), respectively,
Cooelosions; 1) Flecainide suppresses atrial action potential
duration accommodation to heart rate changes in vivo, leading to
rate-dependent atrial effective refractory period prolongation,
which may be important in suppressing atrial fibrillation
. 2) The
drug has frequency- and direction-dependent effects on AV node
conduction, which may lead to selective antiarrhyttmric actions
during AV node reentry .
fJ Am Coll Cardiol 1992 ;19:1335-42)
note atrial fibrillation or prevent its recurrence, or both
.
Sophisticated experimental work (15,16) has confirmed long-
star-ding notions (17) about the reentrant nature of atria]
fibri!hAitn in both animal models (15) and humans (16). We
have reported (IS) that flecainide is able to attenuate the
abbreviation in action potential duration that results from
increased heart rate, resulting in tachycardia-dependent
atrial refractory period prolongation in a variety of animal
species, including humans
. Such an action might account for
the beneficial action of flecainide against reentry at the rapid
rates typical of atria) fibrillation, despite modest changes in
atria) action potential duration at slower frequencies (18,19) .
However, at least one laboratory has reported (20) an
absence of
tachycardia-dependent action potential duration
prolongation by flecainide in atria) tissues,
A
second
potentially paining clinical property ofJlecain-
ide is its ability to terminate atrioventricutar (AV) node
reentrant tachycardia (21-23) . The occurrence of AV node
reentry is determined by the excitation and refractoriness
properties of AV node slow channel tissue (2) .
and the
n735-1a9A9'JSS.5%
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weakness of the calcium channel blocking action of flecain-
ide contrasts with its efficacy against AV node reentry .
Previous experimental studies of the effects of flecainide on
AV node issue have not dealt in depth with two important
potential modulators of the drug's action-frequency and
direction of activation
. Because termination of AV node
reeniry by flecainide usually results from a block in the
retrograde direction (21 .22), it is important that its dose-
dependent actions be analyzed during both anterograde and
retrograde conduction . Furthermore, lachycardia is known
to enhance the conduction-depressing effects of flecainide in
fast-channel tissue
(24) . Whether this also applies to the
effect of flecainide on the AV node is not well known
.
The purpose of the present study was to evaluate the in
vivo actions of flecainide that may underlie its efficacy
against supraventricular arrhythmias . Specific objectives
included the assessment of 1) the rate-dependent effects of
flecainide on the atrial refractory period and action potential
duration (as assessed by monophasic action potentials),
2) the rate-dependent effects of flecainide on AV node
conduction time (as indicated by the AH interval), and
3) the relative actions of flecainide on anterograde and
retrograde AV node conduction.
Methods
Experimental preparation. Fifteen male or female mon-
grel dogs weighing 15 is 25 kg were anesthetized with
morphine (2 mg/kg body weight subcutaneously) and alpha.
chloralose (100 mglkg intravenously) . They were ventilated
through an endotracheal tube with a Harvard-type animal
respirator. Respiratory variables sere adjusted after peri-
odic measurements of arterial blood gases to ensure ade-
quate oxygenation (systemic arterial oxygen saturation
r90%) and physiologic pH )7 .35 to 7 .45)
.
Catheters were inserted into both femoral veins and
arteries and were kept patent with heparinized saline solu-
tion (0 .9%) . A thoracotomy was performed through the
fourth right intercostal space, and the heart was suspended
in a pericardial cradle. Body temperature was monitored by
a thermistor within the chest cavity and was maintained at
37' to 38'C by a homeothermic heating blanket . Two bipolar
Teflon-coated stainless steel plunge electrodes were inserted
into the right atrial appendage. and two electrodes were
inserted into the high lateral right ventricle for recording and
stimulation . Another bipolar electrode was inserted epicar-
dially to record a His bundle electrogram (25) . In eight
experiments . a 6F Franz-type intracardiac contact electrode
catheter (El' Technologies) was introduced by way of the
right femoral vein and positioned in the right atrium to
record a monophasic action potential . Stimulation was ap-
plied using 4-ms square wave pulses at twice the late
diastolic current threshold with a microcomputer-based
stimulator (Digital Cardiovascular Instruments) . The sinus
node was crushed to allow for a wide range of pacing rates .
A Statham P23 ID transducer (Statham Medical Instru-
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meats), eleetrophysiolugic amplifiers (Bloom Ltd .) and a
paper recorder (Siemens-Elema Mingograf 81 or T-16) were
used to record blood pressure, at least three electrocardio-
graphic (ECG) limb leads, intracardiac electrograms and
stimulus artifacts .
Endogenous raga) and hem-adrenergic effects were pre-
rettted to avoid changes due to variation in autonomic tone .
Vagal effects were prevented by surgical division of the
cervical vagi followed by intravenous administration of I mg
of atropine . Beta-adrenergic blockade was produced by
administration of 0.5 mg/kg of nadolol
. Repeated doses of
0.5 mg of atropine and 0.25 mg/kg of nadolol were adminis-
tered every 2 h. This technique has been shown to produce
sustained beta-adrenergic and vagal blockade (26)
.
We have
previously demonstrated (27) that alpha-adrenergic receptor
activation or blockade has no effect on atrial . AV node or
His-Purkinje conduction .
Measurement of electrophysiologic variables . Wencke-
bach cycle length was measured by decreasing the atrial
pacing cycle length by 10 ms every 20 beats until second-
degree AV block occurred. The retrograde Wenckebach
cycle length was measured by a similar method, but with
ventricular pacing instead of atrial pacing, and defined as the
longest cycle length without 1 :1 ventriculoatrial conduction .
The effective refractory period of the atrium and ventricle,
respectively . was measured with the extrastimulus tech-
nique and standard definitions. The AH interval was defined
as the interval from the first rapid atrial activation in the His
electrogram until the first rapid component of the His bundle
potential . The atrial monophasic action potential duration
was measured as the time from local activation R,90% of full
repolarization . Measurements from two separate beats re-
corded at a paper speed of 250 mails were averaged and used
to indicate monophasic action potential duration .
Figure I shmrs representative monophasic action poten-
tials and illustrates the method of measuring their duration .
The ventricular electrogram was always recorded as a low
amplitude signal by the electrode used to monitor the
monophasic action potential and was sometimes superim-
posed on the latter. When this occurred, the portions of the
action potential immediately before and after the ventricular
signal were joined with a smooth curve (as shown by the
dotted line for the first action potential in Fig . 1) to determine
the monophasic action potential duration .
Experimental protocol. Under control conditions, the
atria[
effective refractory period, monophasic action poten-
tial duration, ventricular effective refractory period and AIR
interval were measured over a wide range of basic cycle
lengths (from 300 to 1 .000 ms) . At least 2 min was allowed
after a change in pacing cycle length before measurements
were taken . Wenckebach cycle length and retrograde
Wenckebach cycle length were then determined .
Flecainide acetate it-as infused according to the protocol
shmvn in Table 1 . Ten minutes after the end of each loading
dose, the measurements trade under control conditions were
repeated . Plasma flecainide concentrations were measured
JACC
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Figure L Method of measuring monophusic action potential dura-
tion (MAPD) . The total amplitude of the monophusic action poten-
tial (vertical deflection from line A to 81 was measured and a
horizontal line drawn at 90% of repolarization (that is . AC = 0
.9
x
AB). The time from the intersection of horizontal line C with the
upstroke and repolarization of the
monophon i c
action potential
(MAP) is the monophasic action potential duration (MARD) . When
ventricular depolarization caused
an
artifact during repolarization of
the monophasic action potential . a smooth curve
toned
fine in the
monophasic action potential signals
as drawn between the
monophasic action potential signal proximal and distal to the ven-
tricular electrogram . 2 = ECG lead 11 : VEg = curricular electro-
gram : AEg = atrial electrogram: HEg = His bundle electrogram
.
in samples obtained before and after each electrophysiologic
study to ascertain the stability of drug concentration over the
study interval . Animal handling and experimental proce-
dures were approved by the Animal Care Committee of the
Montreal Heart Institute .
Drug assay . Plasma flecainide concentrations were mea-
sured with high performance liquid chromatography . The
internal standard for flecainide (its positional isomer) was
added (4 µg) to0.5 ml of plasma along with 3 ml of methylene
chloride and 20 mg of sodium chloride
. After 15 s of
agitation, the mixture was centrifuged for 10 min at
3 .0(X1 rpm . The upper layer was aspirated and discarded . and
the solvent layer was removed and evaporated to dryness
under a stream of nitrogen . The residue was reconstituted
Table 1 . Doses of Flecainide Used and Resulting Concentrations
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with 60 µ1 of mobile phase /90%r methano1110%% water in
2 niter of oclanesulfonic acid adjusted to pH 4 with glacial
acetic -rd). A 30-p1 aliquot •.vas injected with a Rhcodyne
712)) injector onto two Sperisorb ODS-1 columns (5-yam
particles) in tandem and detected by a Waters ultraviolet
sensor at a wavelength of 298 nm . The coefficient of varia-
tion ranged from 1% to 2.% at elocentrations of IN to
2 .000 ng/m) .
Statistical analysis, Results are reported as mean values
SEM . Repeated measures were compared with the same
control value by using analysis of variance (29) . Compari-
sons between only two groups of data were made by a
Student t rest
. Least squares regression was used to evaluate
linear correlation, A p value < 0
.05 was taken to indicate
statistical significance
.
Results
The dose regimen used resulted in stable plasma concen-
trations throughout the period of electrophysiologic study
(Table I). Blood pressure was unaltered by flecainide . Mean
flecainide concentrations varied from 0.3 to 1 .8 mg/liter,
spanning the clinically relevant range (29).
Drug effects on atria) and ventricular
refractoriness*
At
long cycle lengths flecainide produced very modest increases
(Fig . 21 in atrial effective refractory period : however. these
increases were grcall; magnifief as cycle length decreased.
For example . dose 3 increased the atrial effective refractory
period by 9 ± 4% at a cycle length of 1 .000 ms but by 36 -_
5% and 55 a 10% (p < 0.001 for each) at cycle lengths of 400
and 300 ms. This action of flecainide was related to changes
in the response of atria[ effective refractory period to chang-
ing atrial activation rate . Under control conditions atrial
effective refractory period decreased with decreasing cycle
length . This phenomenon was blunted by flecainide in a
dose-dependent fashion . and rate-dependent effective refrac-
tory period shortening was completely abolished by the
highest dose of flecainide .
Then, acriot+s rnmznared welt+ the ef/Teris ofjecninide on
rite ventricular ejferrive refractor period . Under control
conditions the ventricular effective refractory period, like
the atrial effective refractory period, decreased at a faster
ventricular pacing rate (Fig . 31 . The decreases in the ven-
Group values are shown as mean
,late
x SE. All loading Oases were gican aver 15 min and were immediately
fnllmcd by the mainmnanae infusion .
Concentrations before and afters lady were memured
w
ith plasma samples oM,atnd ,nnad :a¢ly Salem and after electtophy .cioteeic study. which hewn 10 min
after the end of the Iwding dose .
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Figure 2. Rate-dependent changes in the atrial effective refractory
period IAERPI produced by flecainide . Results are mean values
SE in seven dogs. *p < 0 .05 . **p < 0.01 . ***p < 0.001 for changes
produced by flecainide at any cycle length compared with changes
produced at a length of 1,000 ms. BCL = basic cycle length . See
Table I (or description of doses,
tricolor effective refractory period produced by faster pacing
were not abolished with flecainide . As a result, the modest
effects of flecainide on the ventricular effective refractory
period at slow rates were not altered as the rate increased,
and the drug caused a statistically nonsignificant increase
(approximately 5%) at all cycle lengths,
Rate-dependent drug effects on atria] monophasic action
potential duration . The rate-dependent actions of flecainide
on the atrial effective refractory period could have been due
either to rate-related sodium channel blockade or to alter-
ations in action potential duration . To define the underlying
mechanism . we studied the response of atrial monophasic
action potential duration to changes in basic cycle length in
the presence and absence of flecainide in eight dogs . Flecain-
ide caused a modest dose-dependent increase in monophasic
action potential duration at long cycle lengths (Fig. 4).
Although the action potential duration decreased at a shorter
basic cycle length under control conditions, this phenome-
Figure 3. Dose-dependent changes in the ventricular effective re-
fracioiy pes
;od
( FRP) produced by flecainide . Re u6 shown are
mean values -- SE in seven dogs. BCL = basic cycle length .
BCL (ms)
Figure 4. Rate-dependent changes in atrial monophasic action po-
tential duration (MAPDI produced by flecainide . Results are from a
different set of dogs from those shown in Figures 2 and 3 . r*p <
0 .01 . ***p < 0 .1101 for changes produced by flecainide at any cycle
length compared with changes produced at a cycle length of
1,000 ms. BCL = basic cycle length
.
non was attenuated in a concentration-related way by
flecainide . Consequently, the drug's action on monophasic
action potential duration is much greater at shorter than at
longer cycle lengths . This response to flecainide is quite
similar to the response of the atria] effective refractory
period in a separate set of seven dogs (Fig. 2).
To establish more clearly the role of action potential
duration changes in explaining the effects ofJlecainide on
atrial refractoriness, we evaluated the relation between
action potential duration and the atria) effective refractory
Figure 5. Top panel, Relation between drug-induced changes in the
atrial effective refractory period (AERP) and in monophasic action
potential duration (AMAPD) . Each point represents the mean re-
sults at one cycle length. The correlation coefficients were 0 .93 far
dose I . 0 .99 for dose 2 and 0.97 for dose 3 . Bottom panel, Ratio of
atria[ effective refractory period to monophasic action potential
duration
(ERPIAPD) under control
conditions Isond (iamonds) and
in the presence of flecainide (same symbols for each dose as in the
top panel). Doses I and 2 did not change the ratio, and dose 3
produced small, statistically insignificant changes that appeared to
he tachycardia dependent. BCL = basic cycle length .
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Figure 6. Concentration-response relations for flecainide-induced
increases in Wenckebach cycle length IWBCLI. Results are mean
values
2
SE in seven dogs . *p < 0.05. ***p < 0 .001 compared with
the control value . A = anterograde Wenckebach cycle length
: R =
retrograde Wenckebach cycle length. r = correlation coefficient for
the regression line shown.
period as measured simultaneously in the right atrial append-
age in five dogs. Figure 5 (top) shows the relation between
drug-induced changes in these two variables
. Each point
shows the mean change at a specific cycle length produced
by each dose of flecainide. For each dose. there was a highly
significant correlation between changes in action potential
duration and changes in the atria) effective refractory period .
with correlation coefficients of 0.93 . 0.99 and 0 .97 for doses
I, 2 and 3 . respectively . The slope for the highest dose was
1 .3, indicating that approximately 77% of the flecainide-
induced increase in the atrial effective refractory period
could be attributed to drug-induced changes in action poten-
tial duration . The bottom of the graph shows the ratio of the
atrial effective refractory period to action potential duration
as a function of cycle length under control conditions and in
the presence of doses I to 3 of flecainide . Doses I and 2 did
not alter the atrial effective refractory periodlaction potential
duration ratio
. Dose 3 increased the ratio s lightly . in an
apparently rate-dependent way, but the effect was small and
statistically nonsignificant .
Effects on Wenckebach cycle length
. Flecainide produced
a concentration-dependent increase in Wenckebach cycle
length (Fig. 6). There was a strong ii near correlation between
drug concentration and Wenckebach cycle length (r = 0
.99
for each). Although flecainide caused statistically significant
increases in Wenckebach cycle length during both antero-
grade and retrograde AV node conduction, the drug's effects
were stronger on retrograde conduction
. For example, the
highest dose offlecainide increased retrograde Wenckebach
cycle length by a mean of 39.7% compared with a change of
13 .7% in the anterograde direction. The slope of the concen-
tration-response relation . a n index of potency of drug action .
was significantly steeper in the retrograde (41 ± 7 ms/
iumol'liter
1 ) than in the anterograde direction (17 x
4 ms/ umol'liter- 1 , p < 0.01)
.
Rate-dependent effects on AV conduction, Under control
conditions the AIR interval increased slightly at short pacing
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7 .
Flecainide-induced rate-dependent changes m the AH
interval
. Results are mean values ± SE in seven dogs . up < 0.05 .
-p < IIA1, "*`p < 0
.001 for the change produced by flecainide at
any cycle length compared with the change produced by the same
dose at a cycle length of 1 .000
ms. BCL = basic cycle length .
cycle lengths . with an average increase of I I ± 4 ms from the
longest to the shortest cycle length (Fig. 7). Flecainide
increased the cycle length dependence of the AH interval .
Consequently, the effect of flecainide on the AH interval was
enhanced as activation rate increased . The flecainide-
induced increase in the AH interval at a cycle length of
400 ms averaged 1 .8, 1 .5 and 2 times its effect at 1 .000 ms for
doses I . 2 and 3
. respectively .
Discussion
We have shown that flecainide attenuates the accommo-
dation of atrial action potential duration to increasing heart
rate and that this action is associated with taehyeardia-
dependent increases in the atrial monophasic action poten-
tial duration and refractory period . In addition. flecainide
depresses AV node conduction more at faster heart rates and
ecerts its action preferentially in the retrograde direction .
These properties may contribute in an important way to the
efficacy of flecainide in treating supraventricular arrhyth-
mias .
Relation to the antiarrhylhmic actions of flecainide . The
ability
of class IC agents to terminate atria! fibrillation and
prevent its recurrence is well documented (4-14), but the
mechanism of this action is unknown
. We have shown (18)
that flecainide attenuates the accommodation of the atrial
action potential duration to frequency changes in vitro by
studying atrial tissue samples from a variety of species,
including dogs and humans . This action results in tachycar-
dia-dependent prolongation of action potential duration (18).
Subsequently
. we presented data (30) based on epicardial
activation mapping that suggest that the beneficial effects of
flecainide in a canine model of atrial fibrillation can be
explained by rate-dependent increases in the refractory
period . Kirchhof et al . (31),
studying a class IC drug
currently under development (ORG 7797) . showed that it,
too. appeared to prevent atrial fibrillation, at least in part by
1 340
11 .-A re Al ..
	
IACC Val . 19. No, c,
FLEC .AINIDE AND SUPRAVENTRICULAR TACHYARRHYTHMIAS May 1992:1335-42
suppressing the refractory period shortening that results
from an increased atria) rate . The importance of changes in
atrial refractoriness in suppressing other experimental atrial
reentrant arrhythmias has also been well documented
(32,33)
.
The present study is the first to our knowledge that shows
directly by atrial monophasic action potential recording in
vivo that flecainide produces a tachycardia-dependent pro-
longation of atrial refractoriness by attenuating action poten-
tial duration adaptation to heart rate. These observations
provide a direct link between phenomena previously noted
in isolated atria in vitro (18) and changes in atrial refracto-
riness and arrhythmias in vivo (30,31). In addition to changes
in action potential duration, a portion of the effect of
flecainide on the atrial effective refractory period probably
resulted from increases in the effective refractory period)
action potential duration ratio induced by sodium channel
blockade, particularly with dose 3 (Fig . 5) . Similar rate-
dependent effects have been described for quinidine on
canine ventricular tissue (34) ; however, the analysis in
Figure 5 (top) indicates that action potential duration
changes accounted for >75% of the effective refractory
period prolongation produced by flecainide dose 3.
Flecainide rerminates A V rude rer-sars' by caasing a
block in the retrograde direction (21 .22) .
In the present
study . we have shown that the ability of flecainide to depress
AV node conduction is dependent on both rate and direc-
tion. It is likely that the rapid AV node activation rates of
AV reentrant tachycardias enhance the depressant actions of
flecainide . The tachycardias then terminate preferentially in
the retrograde direction because the actions of flecainide are
stronger on retrograde than on anterograde AV node con-
duction .
Comparison with previous studies of flecainide action . Our
group 118) and Le Grand et al . (20) have found that flecainide
causes rate-dependent prolongations in atrial refractoriness
in vitro. Lc Grand et al . (20) noted rate-dependent increases
in action potential duration to 50% repolarization, but not
action potential duration to 90% repolarization
. They indi-
cate that the maximal concentration that they could use
without producing inexcitability was 0 .5 yrmol'liter ', a
relatively low concentration . It is possible that the differ-
ences between our results and those of Le Grand el al . are
due to differences in both the concentrations and the prep-
arations studied, since therapeutic flecainide concentrations
produced iuexcitability in their tissue samples . The present
work is the first study to analyze changes in atrial monopha-
sic action potential duration caused by flecainide in vivo,
Several investigators (35-38) have reported that flecainide
can suppress AV node conduction . None have commented
on the rate dependence of the drug's action on the AV node,
although one study (37) presents data consistent with tachy-
card ia-dependent slowing of AV node conduction .
Hellestrand et al . (21) noted that in patients with dual AV
node pathways, fiecainide increased refractoriness of the
fast pathway more in the retrograde than in the anterograde
direction . This finding is similar to our observation that
concentration-dependent increases in Wenckehach cycle
length by flecainide are much greater in the retrograde than
in the anterograde direction .
Possible ionic mechanisms. The mechanisms by which
fiecainide increases atrial action potential duration and at-
tenuates accommodation of this variable to rate change is
unknown . Two general voltage- and time-dependent out-
ward currents participate prominently in repolarization-the
transient outward current (1,,,) and the delayed rectifier (I.)
(39) ; I,,, is largely inactivated at rapid rates (39), so that its
inhibition is unlikely to contribute to tachycardia-dependent
prolongation of action potential duration . Although flecain
ide can block I
t, (
40) . this current does not appear to play a
major role in the regularization of dog atrial tissue (41).
Better delineation of the actions of flecainide on atrial
repolarization will require further study of the membrane
currents underlying atrial repolarization at various rates and
their pharmacologic regulation .
Little information is available about how flecainide de-
presses AV node conduction
. Flecainide can block calcium
current (1 ,,) . but this action requires concentrations in
excess of 5 µmol'liter ' (ED51) = 20 µmol-liter ') in frog
ventricular cells (42)
.
Unless the AV node of mammalian
species like dogs and humans is much more sensitive to the
drug. it is unlikely that the action of flecainide on the AV
node at therapeutic concentrations in humans (0 .8 to
2 samol'liter ') is due to inhibition of lc,, . A second possi-
bility is that flecainide slows AV node conduction by inhib-
iting a sodium current-dependent contribution to conduction
in the AV node . Although calcium current is widely accepted
as the main inward current determining conduction in the
AV node
(2),
the ability to carry tetrodotoxin-sensitive
sodium current can clearly be demonstrated in voltage-
clamped AV node preparations (43)
.
The sodium-dependent
component of phase 0 is more important in AV node cells
outside the N region (44), as would be expected from the
more negative rest potential and greater phase 0 upstroke
velocity in the proximal and distal portions of the AV node
(45). The role dependence of flecainide-induced slowing of
AV node conduction could then be accounted for by the use
dependence of drug-induced sodium channel blockade (24)
.
Preferential actions in the retrograde direction might be due
to a critical role of excitability in the AN region during
retrograde propagation as the weak current source of the N
zone aitempts to excite the larger current sink of the
proximal AV node and atrium
.
Potential limitations
. We used combined beta-adrenergic
and muscarinic receptor blockade to prevent complicating
effects from reflex changes during various pacing protocols .
It is possible that intact autonomic tone would alter the
results obtained . However, flecainide itself is not known to
elicit changes in autonomic tone or to interact with the
autonomic nervous system .
A further limitation is imposed by the fact that experi-
ments were performed in anesthetized, open chest dogs .
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Although the anesthetic agent we used . alpha-chloralose .
can alter autonomic t one . it does not appear to have direct
eleetrophysjologic effects on cardiac tissue 146) . Thoracot-
omy and anesthesia exert most of their confounding effects
by altering autonomic tone, and beta-adrenergic and musca-
rinic receptor blockade should therefore minimize complica-
tions created by these aspects of the preparation . Neverthe-
less, it would be useful to verify in patients undergoing
electrophysiologic study whether flecainide has effects sim-
ilar to those we observed in the present study .
We evaluated the effects of flecainide over a concentra-
tion range (0 .8 to 4 gumohliter '), which exceeds the thera-
peutic range in humans (0.8 to 2 tamol liter')
: however, we
have previously shown (18) that flecainide is 2 to 3 times as
potent in its effects on human atria) tissue as on dog atrial
tissue . Mean flecainide concentration at the termination of
atria) fibrillation has been measured at 1 .2 yamohliter -I in
humans (47). corresponding to a concentration of 2
.4 to
3 .6 gcmol-liter- '
in dogs . It is therefore likely that our results
are applicable to effects occurring over the therapeutic range
in humans .
Despite the use of His bundle recordings . we were not
able to distinguish a clear His electrogram during retrograde
ventriculoatrial conduction . It is therefore impossible to
exclude ventricular or His-Purkinje block as the mechanism
for retrograde Wenckebach cycle length prolongation in the
presence of flecainide . On the other hand, ventricular refrac-
toriness was minimally prolonged by the drug (Fig
. 31 . Along
with the known tendency for ventricular and His-Purkinje
refractoriness abbreviation at rapid rates, and the typical
Wenckebach patterns observed, an AV node site for this
action of flecainide seems much more likely .
Clinical implications. Our results give potential insight
into the mechanisms of flecainide action in supraventricular
arrhythmias. Flecainide's ability to attenuate atria) action
potential duration accommodation to tachycardia is a novel
and potentially important mechanism . The resulting tachy-
cardia-dependent action potential duration prolongation is a
highly desirable property lacking in most currently available
agents that prolong action potential duration
(48) . The ability
of flecainide to impair AV node conduction preferentially at
rapid rates and in the retrograde direction is also desirable .
because it results in maximal action during AV node reen-
trant tachycardia with minimal effect on normal anlerograde
AV node conduction during sinus rhythm . Further studies
are indicated to determine the ionic mechanisms of the
action of flecainide on accommodation of action potential
duration and on AV node conduction and to better under-
stand the selectivity
of the latter for retrograde impulse
propagation .
We clack Lion de Repentigny for typing the manuscript . Nancy fennel and
Carol Matthews for expert technical assistance and Riker-3M Pharmaceuti-
cals for supplying flecainide and the internal standard used for drug assay .
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